Recombinant Perisphaeria ruficornis Sulfakinin-1

What is the molecular structure of Perisphaeria ruficornis Sulfakinin-1 and how does it compare to other insect sulfakinins?

Perisphaeria ruficornis Sulfakinin-1 likely shares the characteristic C-terminal heptapeptide core sequence (DY(SO₃)GHM/LRFamide) common to insect sulfakinins, with a sulfated tyrosine residue being critical for its biological activity. Most insect sulfakinins feature this conserved sequence that is essential for receptor binding and activation. When working with recombinant versions, researchers should ensure proper post-translational modifications, particularly tyrosine sulfation, as this significantly impacts receptor affinity. Comparative studies with other insect sulfakinins like those from Leucophaea maderae, which have the sequences DY(SO₃)GHMRFamide and pQDY(SO₃)GHMRFamide, can help understand structure-function relationships . The sulfated and non-sulfated versions may show dramatically different receptor binding affinities, as demonstrated in studies where sulfated peptides typically show EC₅₀ values in the nanomolar range (0.12-0.25 nM) while non-sulfated variants may require micromolar concentrations (around 48 μM) for receptor activation .

What expression systems are recommended for producing biologically active recombinant sulfakinins?

For successful expression of biologically active recombinant sulfakinins, eukaryotic expression systems are generally preferred over prokaryotic systems due to their ability to perform post-translational modifications. Chinese hamster ovary (CHO-K1) cells have been successfully used for expression and functional characterization of sulfakinin receptors and can be adapted for recombinant sulfakinin production . For proper sulfation, co-expression with tyrosylprotein sulfotransferases is often necessary. Baculovirus-insect cell expression systems (Sf9 or Hi5 cells) may provide advantages for insect-derived peptides. When designing expression vectors, include a signal sequence for proper secretion and purification tags (His-tag or FLAG-tag) positioned to avoid interference with the bioactive C-terminal region. Post-expression purification typically involves affinity chromatography followed by HPLC to separate sulfated from non-sulfated peptide forms.

How can researchers verify the biological activity of recombinant Perisphaeria ruficornis Sulfakinin-1?

Verification of biological activity requires a combination of in vitro and in vivo assays. For in vitro testing, calcium mobilization assays using cells expressing the corresponding sulfakinin receptor (SKR) provide quantitative measures of activity. CHO-K1 cells expressing aequorin have been successfully used to measure concentration-dependent luminescence responses with EC₅₀ values in the nanomolar range for sulfated peptides . In vivo, feeding assays in insects can demonstrate the characteristic satiety-inducing effect of sulfakinins. For example, injection of sulfakinin peptides has been shown to reduce food intake in various insects including Tribolium castaneum and Nilaparvata lugens . Additionally, measuring physiological parameters such as changes in trehalose, glycogen, and free fatty acid levels can provide further evidence of biological activity, as sulfakinin injection has been shown to increase trehalose and decrease glycogen and free fatty acid levels in insects like Dendroctonus armandi .

What strategies can overcome the challenges of studying the dual forms (sulfated and non-sulfated) of recombinant sulfakinins in functional assays?

The dual existence of sulfated and non-sulfated forms presents significant challenges in sulfakinin research. To address this complexity, implement a three-pronged approach:

• Separation methodology: Employ cation-exchange chromatography followed by reverse-phase HPLC for effective separation of sulfated and non-sulfated forms. The sulfated peptides typically elute earlier due to the negatively charged sulfate group.

• Mass spectrometry verification: Use LC-MS-MS with multiple reaction monitoring to quantify each form precisely. As demonstrated in Asterias rubens research, this approach can detect specific fragments characteristic of each form .

• Parallel bioassays: Test both forms simultaneously in receptor activation assays using a concentration range spanning six orders of magnitude (10⁻¹² to 10⁻⁶ M) to capture the dramatic potency differences. The typical EC₅₀ values show approximately 400,000-fold difference between sulfated (0.12 nM) and non-sulfated (48 μM) forms in some species .

For in vivo studies, incorporate validation through RNAi knockdown of the natural peptide's gene to create a "clean" background for testing recombinant forms at physiologically relevant concentrations.

How can researchers effectively design RNAi experiments to investigate sulfakinin signaling pathways?

Designing effective RNAi experiments for sulfakinin pathway investigation requires careful consideration of multiple factors:

First, target selection is critical. Design double-stranded RNA (dsRNA) constructs targeting both sulfakinin (SK) and sulfakinin receptor (SKR) genes independently to distinguish between ligand and receptor-dependent effects. For the SK gene, target regions encoding the mature peptide rather than the signal sequence to ensure specificity .

Second, delivery methods should be optimized for your specific insect model. Microinjection is typically most effective for precise dosing in larger insects, while feeding-based delivery can be suitable for long-term studies. Standardize the dsRNA concentration (typically 1-2 μg per insect) and validate knockdown efficiency using RT-qPCR at multiple timepoints post-injection (24h, 48h, 72h) .

Third, phenotypic assays should be comprehensive. Monitor not just feeding behavior but also metabolic parameters including trehalose, glycogen, and free fatty acid levels, which have been shown to change significantly following SK pathway manipulation . Weight measurements should be conducted at consistent times relative to molting or emergence, as baseline values fluctuate during development.

For advanced analysis, combine RNAi with tissue-specific transcriptome analysis to identify downstream effectors. This approach has revealed that SK knockdown affects not only feeding regulatory genes but also metabolic enzymes and other neuropeptide signaling components.

What are the optimal methods for studying interactions between recombinant sulfakinins and their G-protein coupled receptors?

Studying sulfakinin-receptor interactions requires specialized techniques due to the complexity of GPCR signaling. The most effective approach combines heterologous expression systems with multiple readout methodologies:

For binding affinity studies, establish stable cell lines expressing the sulfakinin receptor (e.g., ArSK/CCKR from Asterias rubens or insect SKRs) and use competitive displacement assays with radiolabeled or fluorescently labeled sulfakinins . Calculate Ki values to determine the binding affinity of different sulfakinin variants.

For functional assays, implement multiple readout systems to capture diverse signaling pathways:

• Calcium mobilization using aequorin-expressing cells or calcium-sensitive dyes

• cAMP measurements using ELISA or biosensor approaches

• Receptor internalization using fluorescently tagged receptors

• β-arrestin recruitment assays for determining biased signaling properties

It's crucial to compare sulfated and non-sulfated peptide variants across all assay platforms, as different G-protein coupling may occur. For example, in Asterias rubens, the sulfated ArSK/CCK1 and ArSK/CCK2 showed EC₅₀ values of 0.25 nM and 0.12 nM respectively, while the non-sulfated ArSK/CCK2(ns) showed dramatically reduced potency with an EC₅₀ of 48 μM .

For more advanced analyses, employ biophysical methods such as surface plasmon resonance (SPR) to measure association and dissociation kinetics, providing insights into the temporal aspects of receptor binding.

How should researchers design dose-response experiments for recombinant sulfakinins to account for the dramatic potency differences between sulfated and non-sulfated forms?

When designing dose-response experiments with recombinant sulfakinins, researchers must address the substantial potency disparity between sulfated and non-sulfated forms. A methodologically sound approach includes:

First, establish a logarithmic concentration series spanning at least eight orders of magnitude (10⁻¹³ to 10⁻⁵ M) to capture the full response range of both forms. Based on published data, sulfated forms typically show EC₅₀ values in the sub-nanomolar range (0.12-0.25 nM), while non-sulfated variants may require micromolar concentrations .

Second, implement internal controls within each experiment. Include a reference sulfakinin with established potency (such as drosulfakinin or leucosulfakinin) as a positive control to normalize responses across experimental batches. This is particularly important when comparing results across different receptor expression systems or assay platforms.

Third, verify peptide integrity before each experiment using analytical methods such as HPLC and mass spectrometry to confirm sulfation status and absence of degradation. The presence of even small amounts of desulfated material can significantly confound results.

Finally, analyze data using both individual curve fitting and global analysis approaches to extract accurate potency parameters, particularly when comparing multiple receptor subtypes or mutants.

What factors should be considered when designing in vivo feeding assays to study the satiety effects of recombinant sulfakinins?

Designing rigorous in vivo feeding assays for sulfakinin research requires careful consideration of multiple experimental parameters:

First, standardize the physiological state of the test organisms. Implement a consistent pre-experiment starvation period (typically 24-48 hours for insects depending on species) to ensure uniform motivation to feed . The developmental stage must be precisely controlled, as sulfakinin receptor expression levels vary substantially throughout development.

Second, delivery method optimization is critical. For direct effects, microinjection of the recombinant peptide is preferred, with doses calculated based on body weight (typically 1-10 pmol/mg). Establish injection controls using vehicle-only and heat-inactivated peptide preparations. For sustained effects, consider osmotic mini-pumps or repeated injection protocols with careful monitoring of injection trauma.

Third, implement multiple complementary feeding measurements:

• Quantitative food consumption (weight or volume)

• Feeding bout frequency and duration (using automated monitoring systems)

• Food preference tests (choice assays between different food qualities)

• Post-feeding metabolic changes (trehalose, glycogen, and lipid levels)

Fourth, include genetic validation through parallel experiments with SK or SKR gene knockdown animals (using RNAi techniques) to confirm receptor-mediated effects . This approach helps distinguish specific sulfakinin effects from general physiological responses to peptide administration.

Finally, extend observations beyond immediate feeding to capture delayed effects on metabolism, as illustrated by studies showing that sulfakinin injection leads to increased trehalose and decreased glycogen and free fatty acid levels .

How can researchers accurately determine the tissue distribution and expression patterns of sulfakinin receptors for functional studies with recombinant peptides?

Determining the precise tissue distribution of sulfakinin receptors requires a complementary multi-technique approach:

Begin with transcriptomic analysis across different tissues and developmental stages using RT-qPCR with validated reference genes specific to each tissue type. This provides baseline expression data for receptor mRNA. For sulfakinin receptors, expression has been documented in various tissues including the nervous system, digestive system, and peripheral tissues in multiple species .

Follow with protein-level validation using custom antibodies developed against conserved receptor epitopes. For western blotting, use membrane protein extraction protocols optimized for GPCRs, including appropriate detergents (e.g., n-dodecyl-β-D-maltoside) and protease inhibitors. For immunohistochemistry, enhance specificity by pre-absorbing antibodies with receptor-expressing cells versus control cells.

For cellular resolution, implement RNAscope in situ hybridization or fluorescence in situ hybridization (FISH) techniques, which offer superior sensitivity compared to traditional ISH methods. This is particularly valuable for identifying specific neuronal populations expressing sulfakinin receptors within complex nervous tissues.

Functionally validate expression patterns through tissue-specific receptor knockdown experiments combined with recombinant peptide administration. This approach can reveal which tissues mediate specific physiological responses to sulfakinins, such as feeding regulation or metabolic changes.

Lastly, for advanced studies, develop transgenic reporter lines expressing fluorescent proteins under the control of the sulfakinin receptor promoter, enabling real-time visualization of receptor expression in living tissues.

What mass spectrometry approaches best characterize post-translational modifications in recombinant sulfakinins, particularly tyrosine sulfation?

Characterizing tyrosine sulfation in recombinant sulfakinins requires specialized mass spectrometry approaches due to the labile nature of the sulfate group. The following methodology has proven most effective:

First, implement a multi-stage LC-MS/MS workflow using both positive and negative ionization modes. While positive mode identifies the peptide backbone, negative mode better preserves the sulfate modification. Use low-energy collision-induced dissociation (CID) rather than higher-energy methods to minimize sulfate loss during fragmentation.

Second, employ precursor ion scanning for the diagnostic m/z 97 (HSO₄⁻) ion in negative mode, which specifically identifies sulfated peptides. This approach has successfully identified sulfated peptides in complex samples as demonstrated in studies of Asterias rubens radial nerve cord extracts .

Third, confirm sulfation sites through electron transfer dissociation (ETD) or electron capture dissociation (ECD), which preserve labile modifications better than CID. These techniques can unambiguously locate the sulfation to specific tyrosine residues in the peptide sequence.

For quantitative analysis, establish targeted multiple reaction monitoring (MRM) methods tracking both sulfated and non-sulfated forms simultaneously. This approach can determine the sulfation percentage in recombinant preparations and correlate it with biological activity.

Finally, implement quantitative standard addition methods using synthetic sulfated and non-sulfated peptides for absolute quantification in recombinant preparations.

How can researchers effectively compare the pharmacological properties of recombinant sulfakinins across different species to understand evolutionary conservation?

Cross-species pharmacological comparison of sulfakinins requires a systematic approach addressing both methodological and evolutionary considerations:

First, establish standardized heterologous expression systems for multiple sulfakinin receptors. Chinese hamster ovary (CHO-K1) cells expressing aequorin provide a consistent platform for comparing receptor activation across species . Express receptors from phylogenetically diverse species including hemimetabolous insects (cockroaches, locusts), holometabolous insects (flies, beetles), and other arthropods.

Second, design a peptide test panel including:

• Canonical insect sulfakinins with the DY(SO₃)GHM/LRFamide motif

• Species-specific sulfakinin variants

• Chimeric peptides with systematically altered amino acids

• Both sulfated and non-sulfated counterparts of each peptide

Third, implement consistent assay methodologies across all receptor-peptide combinations. The calcium mobilization assay has proven effective for determining EC₅₀ values that range from sub-nanomolar for sulfated peptides to micromolar for non-sulfated variants . Generate complete dose-response curves (10⁻¹³ to 10⁻⁵ M) for each peptide-receptor pair.

Fourth, analyze data using phylogenetically-aware statistical methods to correct for evolutionary distance when comparing pharmacological parameters. Calculate the sulfation boost ratio (EC₅₀ non-sulfated/EC₅₀ sulfated) for each receptor to quantify sulfation dependence across lineages.

Finally, correlate pharmacological properties with receptor sequence features using molecular modeling and docking simulations to identify key residues determining ligand specificity across evolutionary timescales.

What are the current contradictions in sulfakinin research data and how might researchers design experiments to resolve these inconsistencies?

Several contradictions exist in the sulfakinin research literature that require targeted experimental approaches to resolve:

One major contradiction concerns the relative importance of tyrosine sulfation across different biological contexts. While in vitro receptor studies consistently show 400,000-fold higher potency for sulfated versus non-sulfated peptides , some in vivo studies report more modest differences in physiological effects. To resolve this, researchers should design experiments with paired in vitro and in vivo assays using identical peptide preparations. Specifically, inject both sulfated and non-sulfated recombinant peptides at precisely calculated doses spanning several orders of magnitude, followed by comprehensive physiological measurements including feeding behavior, digestive enzyme secretion, and metabolic parameters.

Another contradiction involves tissue-specific effects. Some studies suggest that sulfakinins act primarily on the digestive system, while others indicate central nervous system targets. Design experiments using tissue-specific receptor knockdown (using CRISPR-Cas9 or conditional RNAi approaches) followed by sulfakinin administration to determine which tissues mediate specific responses.

The third contradiction concerns species-specific differences in sulfakinin function. While feeding inhibition is commonly reported , some species show different or even opposite effects. To address this, conduct comparative studies across phylogenetically diverse species using standardized feeding assays and identical peptide preparations. Include comprehensive metabolic measurements (trehalose, glycogen, lipids) alongside behavioral observations .

Finally, there are contradictions regarding the relationship between sulfakinins and other signaling systems, particularly insulin-like peptides. Design co-administration experiments with sulfakinins and insulin-like peptides, combined with transcriptomic analysis of downstream targets, to map interaction networks and resolve current inconsistencies in the literature.

How can recombinant sulfakinins be effectively utilized in research on insect feeding behavior and potential pest management strategies?

Recombinant sulfakinins offer significant potential for both fundamental research on insect feeding and applied pest management approaches. A comprehensive research strategy includes:

First, develop stable, bioactive recombinant sulfakinin formulations with enhanced stability for field applications. This requires modification of the peptide structure to resist degradation while maintaining receptor binding capacity. Potential approaches include N-terminal acetylation, cyclization, or incorporation of non-natural amino acids at susceptible positions while preserving the critical DY(SO₃)GHM/LRFamide motif.

Second, establish feeding impact profiles across agricultural pest species. Conduct standardized feeding assays using both choice and no-choice paradigms following sulfakinin administration. Research in multiple insect species including Tribolium castaneum, Phormia regina, and Nilaparvata lugens has confirmed feeding inhibition following sulfakinin treatment . Extend these studies to economically important pests like Dendroctonus armandi, where sulfakinin injection has been shown to reduce body weight and increase mortality while altering metabolic parameters .

Third, develop targeted delivery systems compatible with field application. Potential approaches include:

• Peptide-expressing baculovirus vectors

• Transgenic crop plants expressing sulfakinin mimetics

• RNA interference targeting sulfakinin receptors to modify their sensitivity

Fourth, assess ecological safety through non-target organism testing, particularly examining effects on beneficial insects and pollinators. This is critical for developing environmentally responsible pest management tools based on sulfakinin biology.

For comprehensive evaluation, construct a decision matrix incorporating feeding suppression potency, implementation feasibility, production costs, and ecological impact to guide research priorities.

What approaches can researchers use to study the relationship between sulfakinin signaling and other neuropeptide systems in regulating physiological processes?

Understanding the integration of sulfakinin signaling with other neuropeptide systems requires systematic multi-level analysis:

Begin with transcriptomic and neuropeptidomic profiling following sulfakinin pathway manipulation. Use RNA-seq to identify genes whose expression changes after treatment with recombinant sulfakinins or following RNAi knockdown of sulfakinin or its receptor . This approach can reveal regulatory relationships with other neuropeptide systems such as insulin-like peptides, allatostatin, corazonin, and tachykinin pathways.

Implement co-localization studies combining in situ hybridization for sulfakinin receptor mRNA with immunohistochemistry for other neuropeptides. This approach identifies neuronal populations potentially capable of integrating multiple peptide signals. Focus particularly on brain regions associated with feeding regulation and the stomatogastric nervous system.

Conduct co-administration experiments combining recombinant sulfakinins with other key neuropeptides at varying ratios and sequences of administration. Measure physiological responses including feeding behavior, digestive enzyme secretion, and metabolic parameters (trehalose, glycogen, and free fatty acid levels) . This approach can reveal additive, synergistic, or antagonistic interactions between signaling systems.

Employ receptor heteromerization studies using biophysical techniques such as FRET (Fluorescence Resonance Energy Transfer) to determine if sulfakinin receptors physically interact with other neuropeptide receptors, potentially forming functional heteromers with altered signaling properties.

Finally, use CRISPR-Cas9 to generate double mutants affecting both sulfakinin and other neuropeptide systems to assess genetic interactions and hierarchical relationships between parallel regulatory pathways.

What considerations are important when designing and interpreting comparative studies of sulfakinin function across different insect orders?

Designing rigorous comparative studies of sulfakinin function across insect orders requires addressing several methodological challenges:

First, account for evolutionary divergence in peptide sequences. While the C-terminal motif is generally conserved, N-terminal variations can significantly impact receptor binding and stability. Design experiments using both species-specific sulfakinins and standardized canonical sequences. For comprehensive comparison, include sulfakinins from hemimetabolous insects (e.g., Leucophaea maderae, Periplaneta americana), holometabolous insects (e.g., Drosophila melanogaster, Tribolium castaneum), and non-insect arthropods .

Second, standardize physiological contexts across species with dramatically different life histories. Implement stage-specific testing protocols considering equivalent developmental stages rather than absolute age. For feeding studies, the starvation duration should be scaled to species-specific metabolic rates rather than using identical timeframes. For example, 24-hour starvation may be appropriate for some species but insufficient for others with different metabolic profiles .

Third, account for receptor expression variability. Quantify sulfakinin receptor expression levels across equivalent tissues in different species using RT-qPCR with carefully validated reference genes. This is essential for interpreting differential sensitivity to sulfakinin administration.

Fourth, consider phylogenetic relationships in data analysis. Apply phylogenetically controlled statistical methods to distinguish true functional divergence from artifacts of evolutionary history. This approach has revealed that while feeding regulation by sulfakinins is broadly conserved, the specific mechanisms and sensitivity can vary considerably across insect orders.

Finally, incorporate environmental context. Test sulfakinin effects under different nutritional states and environmental conditions relevant to each species' ecology to identify context-dependent functional variations.

How might high-throughput screening approaches be optimized for identifying novel sulfakinin receptor agonists and antagonists?

Developing effective high-throughput screening (HTS) platforms for sulfakinin receptor ligands requires specialized approaches addressing the unique properties of these signaling systems:

First, establish robust cell-based screening platforms using bioluminescence resonance energy transfer (BRET) or time-resolved fluorescence resonance energy transfer (TR-FRET) technologies. These offer superior signal-to-noise ratios compared to traditional fluorescence-based assays and are less prone to compound interference. Engineer stable cell lines expressing sulfakinin receptors (SKRs) coupled to appropriate biosensors for detecting either G-protein activation or β-arrestin recruitment.

Second, develop multiplex screening approaches that simultaneously assess multiple functional outcomes. This is particularly important for SKRs, which can couple to multiple G-protein subtypes. Design the assay to capture Gq (calcium mobilization), Gs (cAMP production), and β-arrestin recruitment in parallel to identify ligands with biased signaling properties.

Third, optimize screening libraries with focused peptide-mimetic compound collections enriched for structures likely to interact with the sulfakinin binding pocket. Include computational pre-screening based on molecular docking to the predicted SKR binding site.

Fourth, implement machine learning approaches trained on known sulfakinin structures to predict activity of novel compounds and guide iterative optimization of hits. This approach can dramatically accelerate the discovery of peptide and non-peptide SKR modulators with improved properties for research applications.

Finally, validate hits through orthogonal assays including competitive binding studies with labeled sulfakinins and functional studies in relevant insect tissue preparations before progressing to in vivo testing.

What recent technological advances might be applied to better understand the molecular mechanisms of sulfakinin receptor activation?

Recent technological breakthroughs offer unprecedented opportunities to elucidate sulfakinin receptor activation mechanisms:

Cryo-electron microscopy (cryo-EM) represents perhaps the most significant advancement for studying sulfakinin receptor structure. While no SKR structures have been published to date, the recent successes with other class A GPCRs provide a template for SKR structural studies. Researchers should focus on generating stable receptor preparations through systematic introduction of thermostabilizing mutations and use of conformational stabilizing nanobodies. The resulting structures would reveal the precise binding mode of sulfated versus non-sulfated peptides and explain the dramatic 400,000-fold potency difference observed in functional studies .

Single-molecule fluorescence resonance energy transfer (smFRET) offers another powerful approach for studying receptor conformational dynamics. By strategically placing fluorophores at key positions within the receptor structure, researchers can observe real-time conformational changes during ligand binding and activation. This technique is particularly valuable for detecting subtle differences in receptor activation mechanisms between sulfated and non-sulfated peptides.

Hydrogen-deuterium exchange mass spectrometry (HDX-MS) provides complementary structural information by measuring solvent accessibility changes upon ligand binding. This approach can identify regions of the receptor that undergo conformational changes specific to sulfated peptide binding.

Advanced molecular dynamics simulations using specialized force fields that accurately represent sulfated tyrosine residues can provide atomic-level insights into receptor-ligand interactions. Microsecond-timescale simulations can capture the complete activation process and identify key interaction networks that explain sulfation-dependent potency differences.

CRISPR-based mutagenesis combined with high-throughput functional screening enables systematic evaluation of all possible amino acid substitutions in key receptor regions, generating comprehensive structure-function maps of residues critical for sulfakinin binding and receptor activation.

How might integrative multi-omics approaches advance our understanding of sulfakinin signaling networks and their evolutionary conservation?

Integrative multi-omics approaches offer powerful frameworks for comprehensively mapping sulfakinin signaling networks across evolutionary timescales:

First, implement parallel transcriptomics, proteomics, and metabolomics analyses following sulfakinin administration or receptor manipulation across phylogenetically diverse species. This three-tier approach captures not only immediate gene expression changes but also subsequent protein-level alterations and ultimate metabolic outcomes. Studies in Dendroctonus armandi have already shown that sulfakinin treatment affects trehalose, glycogen, and free fatty acid levels , but comprehensive metabolomic profiling would reveal additional downstream effects.

Second, apply temporal multi-omics sampling to construct dynamic network models. Collect samples at multiple timepoints (e.g., 30 minutes, 2 hours, 6 hours, 24 hours) post-treatment to distinguish primary from secondary responses and construct detailed signaling cascade models. This approach can reveal how the immediate receptor-proximal events propagate through cellular networks to produce physiological outcomes.

Third, employ comparative phylogenetic approaches to identify conserved versus species-specific network components. By mapping sulfakinin-responsive genes and proteins across evolutionary space, researchers can distinguish core ancestral functions from more recently evolved regulatory connections. This evolutionary perspective is particularly valuable for understanding how sulfakinin networks have been adapted for specialized functions across different insect lineages.

Fourth, implement single-cell multi-omics to resolve cell-type-specific responses to sulfakinin signaling. This approach is especially relevant for understanding sulfakinin function in heterogeneous tissues like the brain, where different neuronal populations may respond distinctly to the same signal.

Finally, integrate these multi-omics datasets with structural biology and pharmacological studies to create comprehensive multi-scale models connecting molecular events at the receptor level to organism-wide physiological responses.